HIV Pre-Exposure Prophylaxis (PrEP) Guidelines
Initial Assessment and Testing
- A negative HIV test is mandatory before initiating PrEP, preferably using a combination antigen-antibody assay (4th generation test), as recommended by the CDC and WHO 1, 2
- Serum creatinine and estimated glomerular filtration rate must be performed within 7 days before starting PrEP, with an evidence rating of AIII 1, 2
- Hepatitis B surface antigen (HBsAg) testing is required to assess for active hepatitis B infection, as recommended by the CDC, American Medical Association, and WHO 1, 3, 2
- Comprehensive testing for gonorrhea and chlamydia (at all relevant anatomical sites based on sexual practices) and syphilis serology is recommended, with an evidence rating of AIIa 1, 3, 2
- Hepatitis C antibody testing is recommended, especially for high-risk individuals, with an evidence rating of AIIa 1, 2
- Pregnancy testing is required for women before initiating PrEP, as recommended by the CDC and American Medical Association 4, 1
Ongoing Monitoring and Testing
- HIV RNA testing should be performed if acute HIV infection is suspected, with an evidence rating of AIII 1, 3
- PrEP prescriptions should not exceed 90 days without interval HIV testing, as recommended by the CDC and WHO 1, 2
Regular monitoring should include:
Test Frequency HIV antibody/antigen test Every 2-3 months Renal function Every 3-6 months STI screening Every 3 months Pregnancy testing (for women) At each visit Creatinine level testing Every 6 months More frequent monitoring is required for patients >50 years old, those with baseline creatinine clearance <90 mL/min, or those with hypertension or diabetes, as recommended by the CDC and American Medical Association 1, 2
Follow-up Visits and Adherence Support
- A follow-up visit 30 days after PrEP initiation is recommended for HIV testing, assessment of adverse effects, and adherence support, as recommended by the CDC and WHO 1, 2
- Adherence support should be provided at each follow-up visit to assess and address barriers to PrEP adherence, with a strength of evidence level of II 4, 3, 1, 5
- Strategies to support adherence include regular adherence counseling, personal telephone and interactive text reminders, and integration with other services for people with substance use disorders, as recommended by the CDC and WHO 2
- The Centers for Disease Control and Prevention (CDC) recommends a standard daily regimen of one tablet of Truvada (TDF 300 mg/FTC 200 mg) taken orally once daily for individuals at high risk of HIV infection, including men who have sex with men (MSM), transgender women, and people who inject drugs, with an evidence rating of AIa 4, 1, 5, 2
PrEP Regimens and Contraindications
- Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is the primary regimen for all populations at high risk of HIV infection, with alternative options including emtricitabine/tenofovir alafenamide (TAF/FTC) for men who have sex with men and transgender women, and long-acting injectable cabotegravir administered at 8-week intervals, as recommended by the American College of Physicians and CDC 3, 2, 5
- Event-driven (2-1-1) TDF/FTC may be considered as an alternative to daily PrEP for MSM with infrequent sexual exposures, with an evidence rating of AIa, as recommended by the CDC and WHO 1, 5
- Absolute contraindications for PrEP include active HIV infection, and creatinine clearance <60 mL/min for TDF-based PrEP, as stated by the FDA and WHO 2
- Relative contraindications include osteopenia or osteoporosis, and chronic hepatitis B virus infection, according to the American Gastroenterological Association and National Osteoporosis Foundation (NOF) 2
Special Considerations
- Undiagnosed acute HIV infection: Starting PrEP during acute HIV infection can lead to resistance (typically M184V/I mutation), always rule out acute infection before starting PrEP, as recommended by the CDC and WHO 1
- Consider doxycycline post-exposure prophylaxis (doxyPEP) to reduce incidence of syphilis by 73-87% and chlamydia by 70-88%, as recommended by the CDC 6
- The CDC recommends an immediate transition from non-occupational post-exposure prophylaxis (nPEP) to Pre-Exposure Prophylaxis (PrEP) for persons with anticipated repeat or ongoing potential HIV exposures, and complete HIV testing should be done at the completion of the nPEP regimen with prompt transition to a recommended PrEP regimen 7